MB
Elite in Cholangiocarcinoma (Bile Duct Cancer)

Dr. Mitesh J. Borad

Mayo Clinic - Arizona
Phoenix, AZ
Elite
 in Cholangiocarcinoma (Bile Duct Cancer)
On Staff At
Specialties:Hematology | Oncology | Hematology Oncology
Experience:23 Years
Clinical Trials:Currently Recruiting for 3 Trials
Accepts:New PatientsMedicare
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Mitesh J. Borad's experience treating your condition:
About Dr. Mitesh J. Borad

Mitesh Borad is a Hematologist and an Oncologist in Phoenix, Arizona. Borad has been practicing medicine for over 23 years and is rated as an Elite expert by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). He is also highly rated in 20 other conditions, according to our data. His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Gallbladder Cancer, Pancreatic Cancer, and Liver Cancer. He is licensed to treat patients in Louisiana, California, and Arizona. Borad is currently accepting new patients.

His clinical research consists of co-authoring 176 peer reviewed articles and participating in 26 clinical trials in the past 15 years. In particular, he has co-authored 58 articles and participated in 11 clinical trials in the study of Cholangiocarcinoma (Bile Duct Cancer).

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Mitesh J. Borad it is best to call his office and ask if your insurance is accepted.

Accepts Medicare
Call to see if your plan is accepted.
Locations
5777 E Mayo Blvd, Phoenix, AZ 85054
Background & Education
Graduate Institution
Rowan University School Of Osteopathic Medicine, 2000
Specialties
Hematology
Oncology
Hematology Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Mayo Clinic Hospital - Arizona
Languages Spoken
English
Gujarati
Hindi
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

23 Clinical Trials
A Phase I, Multi-Center, Open Label, Dose De-Escalation and Expansion Study of Gemcitabine and Cisplatin With AG120 or Pemigatinib for Advanced Cholangiocarcinoma
Enrollment Status: Recruiting
Publish Date: June 27, 2022
Intervention Type: Drug
Study Drugs: CisplatinGemcitabineIvosidenibPemigatinib
Study Phase: Phase 1
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Enrollment Status: Recruiting
Publish Date: November 17, 2022
Intervention Type: Drug
Study Drug: PT-112
Study Phase: Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma
Enrollment Status: Recruiting
Publish Date: April 28, 2022
Intervention Type: Biological
Study Drugs: VV1Cemiplimab
Study Phase: Phase 2
Pilot Study of Ponatinib in Biliary Cancer Patients With FGFR2 Fusions
Enrollment Status: Completed
Publish Date: November 25, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy
Enrollment Status: Completed
Publish Date: July 15, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: December 19, 2017
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Study of a Rapid Access Platform for Investigational Drugs (RAPID) in Advanced Cancers
Enrollment Status: Completed
Publish Date: June 06, 2019
Intervention Type: Other, Drug
Study Phase: Early Phase 1
Phase I Trial of Intratumoral Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta in Patients With Sorafenib Refractory/Intolerant Hepatocellular Carcinoma, Advanced Solid Tumors With Liver Predominant Locally Advanced/Metastatic Disease or Subcutaneous/Cutaneous Lesions
Enrollment Status: Active, not recruiting
Publish Date: October 10, 2022
Intervention Type: Other, Biological
Study Drug: Recombinant Vesicular Stomatitis Virus-expressing Interferon-Beta
Study Phase: Phase 1
A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy
Enrollment Status: Completed
Publish Date: October 24, 2022
Intervention Type: Drug
Study Drug: M7824
Study Phase: Phase 2
A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types
Enrollment Status: Active, not recruiting
Publish Date: August 29, 2022
Intervention Type: Genetic
Study Phase: Phase 1
A Single-Arm Feasibility Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk Intrahepatic Cholangiocarcinoma
Enrollment Status: Active, not recruiting
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drugs: CisplatinGemcitabineNab-Paclitaxel
Study Phase: Phase 2
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: May 07, 2015
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Enrollment Status: Terminated
Publish Date: July 15, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
Enrollment Status: Completed
Publish Date: December 16, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 3
Phase II Trial of Trifluridine/Tipiracil in Combination With Irinotecan in Biliary Tract Cancers
Enrollment Status: Active, not recruiting
Publish Date: September 22, 2022
Intervention Type: Drug
Study Drugs: IrinotecanIrinotecan HydrochlorideTrifluridineTipiracil Hydrochloride
Study Phase: Phase 2
A Randomized Phase II Open Label Study to Assess the Efficacy & Safety of Gemcitabine + Abraxane® With or Without ODSH (2-0, 3-0 Desulfated Heparin) as First Line Treatment of Metastatic Pancreatic Cancer
Enrollment Status: Terminated
Publish Date: June 06, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase Ib, Open-Label, Dose- Escalation Trial of ACY-1215 in Combination With Gemcitabine and Cisplatin in Patients With Unresectable or Metastatic Cholangiocarcinoma
Enrollment Status: Withdrawn
Publish Date: May 30, 2017
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Study of the Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: May 11, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study
Enrollment Status: Active, not recruiting
Publish Date: April 28, 2022
Intervention Type: Drug
Study Drugs: BL-8040PembrolizumabChemotherapy of Onivyde
Study Phase: Phase 2
A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma
Enrollment Status: Completed
Publish Date: October 22, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
Enrollment Status: Completed
Publish Date: December 09, 2022
Intervention Type: Drug
Study Drugs: Bintrafusp AlfaGemcitabineCisplatin
Study Phase: Phase 2/Phase 3
A Phase I/IIA Study of ABC294640 Alone and in Combination With Hydroxychloroquine Sulfate in the Treatment of Patients With Advanced, Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma
Enrollment Status: Completed
Publish Date: July 11, 2022
Intervention Type: Drug
Study Drugs: ABC294640Hydroxychloroquine Sulfate
Study Phase: Phase 2
View 20 Less Clinical Trials -
176 Total Publications
Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma.
Journal: Targeted oncology
Published: August 11, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
TB
Dr. Tanios Bekaii
Oncology
Mayo Clinic - Arizona
Elite
Highly rated in
24
conditions
Oncology
Mayo Clinic - Arizona

Mayo Clinic

Mayo Clinic - Arizona

5777 E Mayo Blvd, 
Phoenix, AZ 

Tanios Bekaii is an Oncologist in Phoenix, Arizona. Bekaii has been practicing medicine for over 31 years and is rated as an Elite expert by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). He is also highly rated in 24 other conditions, according to our data. His top areas of expertise are Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, and Pancreatic Ductal Adenocarcinoma. He is licensed to treat patients in Arizona.

CW
Dr. Christina S. Wu
Hematology | Oncology
Mayo Clinic - Arizona
Distinguished
Highly rated in
18
conditions
Hematology
Oncology
Mayo Clinic - Arizona

Mayo Clinic

Mayo Clinic - Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
 10.7 mi

Christina Wu is a Hematologist and an Oncologist in Scottsdale, Arizona. Wu has been practicing medicine for over 21 years and is rated as a Distinguished expert by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). She is also highly rated in 18 other conditions, according to our data. Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Lynch Syndrome, Cholangiocarcinoma (Bile Duct Cancer), and Liver Embolization. She is licensed to treat patients in Ohio and Arizona. Wu is currently accepting new patients.

MK
Dr. Madappa N. Kundranda
Hematology Oncology | Oncology | Hematology
Distinguished
Highly rated in
22
conditions
Hematology Oncology
Oncology
Hematology

Banner Health

Banner MD Anderson Cancer Center Clinic

2946 E Banner Gateway Dr, 
Gilbert, AZ 
 23.5 mi

Madappa Kundranda is a Hematologist Oncology specialist and an Oncologist in Gilbert, Arizona. Kundranda has been practicing medicine for over 23 years and is rated as a Distinguished expert by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). He is also highly rated in 22 other conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, and Familial Colorectal Cancer. He is licensed to treat patients in Ohio and Arizona. Kundranda is currently accepting new patients.